骨代谢标志物在多发性骨髓瘤中的临床应用

翟云芝; 张浩然; 翟云芝; 张浩然

doi:10.13898/j.cnki.issn.1000-2200.2018.09.004

[1]

KRISTINSSON SY,MINTER AR,KORDE N,et al.Bone disease in multiple myeloma and precursor disease:novel diagnostic approaches and implications on clinical management[J].Expert Rev Mol Diagn,2011,11(6):593.

[2]

ROODMAN GD.Pathogenesis of myeloma bone disease[J].Leukemia,2009,23(3):435.

[3]

SEIBEL MJ.Clinical use of markers of bone turnover in metastatic bone disease[J].Nat Clin Pract Oncol,2005,2(10):504.

[4]

WU ZX,GAO MX,SANG HX,et al.Surgical treatment of osteoporotic thoracolumbar compressive fractures with open vertebral cement augmentation of expandable pedicle screw fixation:a biomechanical study and a 2-year follow-up of 20 patients[J].J Surg Res,2012,173(1):91.

[5]

YANG J,HE J,WANG J,et al.Constitutive activation of p38 mark in tumor cells contributes to osteolytic bone lesions in multiple myeloma[J].Leukemia，2012,26(9):2114.

[6]

褚彬,陆敏秋,吴梦青,等.多发性骨髓瘤骨病临床特点及监测骨代谢标志物的临床意义[J].中华医学杂志,2016,96(18):1424.

[7]

毛鑫萍,吾为一,黄宏,等.骨代谢生化指标与女性年龄及骨密度的相关性[J].中华核医学与分子影像杂志,2015,35(6):478.

[8]

王旭,张会英,娄路馨,等.脊柱退行性疾病需手术治疗患者骨代谢指标与骨密度关系的研究[J].中华检验医学志,2016,39(4):267.

[9]

CHU B,LU MQ,WU MQ,et al.Clinical characteristics of bone disease in multiple myeloma and clinical significance of monitoring bone metabolic markers[J].Zhonghua Yi Xue Za Zhi,2016,96(18):1424.

[10]

MORGAN GJ,DAVIES FE,GREGORY WM,et al.Effects of induction and maintenance plus long-term bisphosphonates on bone disease——in patients with multiple myeloma:the medical research council myeloma Ⅸ Trial[J].Blood,2012,119(23):5374.